Biocon Biologics and Civica, Inc. Partner to Increase Insulin Aspart Access in the US

Biocon Biologics and Civica, Inc. have announced a collaboration to expand access to insulin aspart in the United States. The press release, titled 'Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States,' will also be available on Biocon's website. This collaboration aims to address the growing demand for affordable insulin in the US market. Biocon's Global Head of Corporate Brand and Communications, Seema Ahuja, expressed excitement about the partnership, which will help make insulin more accessible to patients in need.

Biocon Ltd is an Indian biopharmaceutical company that develops and produces innovative therapies for diabetes, cancer, and autoimmune diseases.

Top Pharmaceuticals Stocks

Stock Name	MCap(Cr)	P/E Ratio	3Y Stock Ret.
Stock Name	MCap(Cr)	P/E Ratio	3Y Stock Ret.
Sun Pharmaceutical Industries Ltd NSE: SUNPHARMA	3,82,274	32.42	24.74%
Divi'S Laboratories Ltd NSE: DIVISLAB	1,45,483	70.38	9.62%
Cipla Ltd NSE: CIPLA	1,13,671	22.82	15.1%
Torrent Pharmaceuticals Ltd NSE: TORNTPHARM	99,772	53.58	28.6%
Mankind Pharma Ltd NSE: MANKIND	94,505	48.87	-